Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic natural killer cells DVX201
- Development stage
- Phase 1
- Lead developer
- Coeptis Pharmaceuticals
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
A preparation of allogeneic, cord-blood derived natural killer (NK) cells with potential cytolytic and antineoplastic activities. Upon administration, these NK cells may directly lyse cancer cells and secrete pro-inflammatory cytokines to stimulate a systemic immune response against cancer. The therapy is being developed as a cell therapy platform for the treatment of relapsed/refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), myeloproliferative disorders, COVID-19 pneumonia, influenza, and respiratory syncytial virus (RSV). The product is manufactured from pooled donor CD34+ hematopoietic stem and progenitor cells using Notch-mediated cell expansion technology. Clinical trials have shown that the product is well-tolerated with no dose-limiting toxicities observed in Phase 1 studies[1][2][3][4][5][6][7].
- Brand names
- DVX201-COV-01DVX-201-COV-01DVX 201-COV-01
- Other names
- allogeneic natural killer cells DVX201
Beyond the preview
Go deeper on allogeneic natural killer cells DVX201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic natural killer cells DVX201.